Stoke Therapeutics (NASDAQ:STOK) Earns Buy Rating from HC Wainwright

Stoke Therapeutics (NASDAQ:STOK)‘s stock had its “buy” rating reiterated by analysts at HC Wainwright in a research note issued on Wednesday, Benzinga reports. They presently have a $35.00 price objective on the stock. HC Wainwright’s price target suggests a potential upside of 168.20% from the company’s previous close.

A number of other research analysts also recently issued reports on the stock. Wedbush reiterated an “outperform” rating and set a $17.00 target price on shares of Stoke Therapeutics in a research report on Thursday, July 11th. Leerink Partnrs upgraded shares of Stoke Therapeutics to a “strong-buy” rating in a report on Friday, October 11th. Leerink Partners began coverage on Stoke Therapeutics in a report on Monday, October 14th. They issued an “outperform” rating and a $18.00 price target on the stock. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $22.00 target price on shares of Stoke Therapeutics in a research report on Thursday, August 8th. One research analyst has rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, Stoke Therapeutics presently has an average rating of “Buy” and a consensus price target of $20.83.

Stoke Therapeutics Trading Down 0.4 %

STOK stock opened at $13.05 on Wednesday. Stoke Therapeutics has a 1-year low of $3.77 and a 1-year high of $17.58. The stock has a 50-day moving average price of $13.25 and a 200-day moving average price of $13.71. The firm has a market cap of $687.06 million, a PE ratio of -5.99 and a beta of 0.95.

Stoke Therapeutics (NASDAQ:STOK) last issued its quarterly earnings results on Wednesday, August 7th. The company reported ($0.46) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.57) by $0.11. The firm had revenue of $4.83 million for the quarter, compared to analyst estimates of $3.33 million. Stoke Therapeutics had a negative return on equity of 57.89% and a negative net margin of 683.35%. On average, analysts forecast that Stoke Therapeutics will post -2.1 earnings per share for the current year.

Insider Activity

In other Stoke Therapeutics news, major shareholder Skorpios Trust sold 1,937,500 shares of Stoke Therapeutics stock in a transaction on Thursday, September 19th. The shares were sold at an average price of $14.05, for a total transaction of $27,221,875.00. Following the transaction, the insider now directly owns 8,906,181 shares of the company’s stock, valued at $125,131,843.05. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 11.30% of the company’s stock.

Hedge Funds Weigh In On Stoke Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of STOK. Los Angeles Capital Management LLC boosted its position in Stoke Therapeutics by 54.3% in the third quarter. Los Angeles Capital Management LLC now owns 103,005 shares of the company’s stock worth $1,266,000 after purchasing an additional 36,240 shares during the last quarter. Mesirow Financial Investment Management Inc. purchased a new position in shares of Stoke Therapeutics in the 3rd quarter worth about $192,000. Healthcare of Ontario Pension Plan Trust Fund grew its position in Stoke Therapeutics by 426.1% during the second quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 1,387,200 shares of the company’s stock valued at $18,741,000 after buying an additional 1,123,500 shares during the period. Lynx1 Capital Management LP increased its holdings in Stoke Therapeutics by 40.3% during the second quarter. Lynx1 Capital Management LP now owns 5,185,191 shares of the company’s stock worth $70,052,000 after buying an additional 1,488,371 shares during the last quarter. Finally, The Manufacturers Life Insurance Company raised its position in Stoke Therapeutics by 16.7% in the second quarter. The Manufacturers Life Insurance Company now owns 13,964 shares of the company’s stock worth $189,000 after acquiring an additional 1,994 shares during the period.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.